推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

MOLECULAR CANCER THERAPEUTICS

2022年12月最新中科院JCR期刊分区表数据(升级版)已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 MOL CANCER THER最新评论:一审1个半月,2个月修回,二审1周接收。 (2022-07-02)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中科院分区:   是否OA期刊:   结果排序:

按研究方向查看:


MOLECULAR CANCER THERAPEUTICS期刊基本信息Hello,您是该期刊的第66714位访客

基本信息 登录收藏
期刊名字MOLECULAR CANCER THERAPEUTICSMOLECULAR CANCER THERAPEUTICS

MOL CANCER THER

LetPub评分
7.9
51人评分
我要评分

声誉
8.8

影响力
6.7

速度
9.6

期刊ISSN1535-7163
微信扫码收藏此期刊
E-ISSN1538-8514
2021-2022最新影响因子
(数据来源于搜索引擎)
6.009 点击查看影响因子趋势图
2021-2022自引率1.40%点击查看自引率趋势图
h-index 157
CiteScore
CiteScoreSJRSNIPCiteScore排名
10.201.8311.211
学科分区排名百分位
大类:Medicine
小类:Oncology
Q143 / 360
大类:Medicine
小类:Cancer Research
Q139 / 210

期刊简介Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.
期刊官方网站http://mct.aacrjournals.org/
期刊投稿网址http://mct.msubmit.net/cgi-bin/main.plex
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足MOLECULAR CANCER THERAPEUTICS的语言要求,还能让MOLECULAR CANCER THERAPEUTICS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被MOLECULAR CANCER THERAPEUTICS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问No
通讯方式AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404
出版商American Association for Cancer Research Inc.
涉及的研究方向医学-肿瘤学
出版国家或地区UNITED STATES
出版语言English
出版周期Monthly
出版年份2001
年文章数 230点击查看年文章数趋势图
Gold OA文章占比2.94%
研究类文章占比:
文章 ÷(文章 + 综述)
93.04%
WOS期刊SCI分区
2021-2022年最新版
WOS分区等级:2区

按学科分区
ONCOLOGY Q2Q2Q3
中科院《国际期刊预警
名单(试行)》名单
2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2021年01月发布的2020版:不在预警名单中
中科院SCI期刊分区
2022年12月最新升级版
点击查看中科院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 1区2区4区
ONCOLOGY
肿瘤学
2区2区2区
中科院SCI期刊分区
2021年12月基础版
大类学科小类学科Top期刊综述期刊
医学 2区2区3区
ONCOLOGY
肿瘤学
1区3区3区
中科院SCI期刊分区
2021年12月升级版
大类学科小类学科Top期刊综述期刊
医学 1区2区3区
ONCOLOGY
肿瘤学
4区1区2区
中科院SCI期刊分区
2020年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 4区2区1区
ONCOLOGY
肿瘤学
4区4区2区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1535-7163%5BISSN%5D
平均审稿速度网友分享经验:
平均3月
平均录用比例网友分享经验:
约50%
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在MOLECULAR CANCER THERAPEUTICS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 MOLECULAR CANCER THERAPEUTICS期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 MOLECULAR CANCER THERAPEUTICS中科院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
MOLECULAR CANCER THERAPEUTICS上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中科院SCI期刊分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发表论文
  • 中科院SCI期刊分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144716.20
    NATURE REVIEWS CANCER39677.10
    Nature Reviews Clinical Oncology12763.50
    LANCET ONCOLOGY27456.90
    ANNALS OF ONCOLOGY21047.30
    JOURNAL OF CLINICAL ONCOLOGY49440.90
    CANCER CELL29541.90
    SEMINARS IN CANCER BIOLOGY13421.10
    CLINICAL CANCER RESEARCH29219.80
    CANCER TREATMENT REVIEWS11620.90
    中科院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE527113
    Frontiers in Pharmacology372258
    BIOMEDICINE & PHARMACOTHERAPY360830
    JOURNAL OF ETHNOPHARMACOLOGY331795
    Frontiers in Immunology329090
    Frontiers in Oncology316562
    Theranostics277973
    Molecular Medicine Reports270305
    International Journal of Nanomedicine268198
    CANCER LETTERS267670
  •  

    MOLECULAR CANCER THERAPEUTICS MOLECULAR CANCER THERAPEUTICS
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Breast Cancer

    Author: Peng, Peng; Qiang, Xiaoyan; Li, Guoyu; Li, Lin; Ni, Shumao; Yu, Qi; Sourd, Laura; Marangoni, Elisabetta; Hu, Chao; Wang, Dong; Wu, Di; Wu, Frank
    Journal: MOLECULAR CANCER THERAPEUTICS. 2023; Vol. 22, Issue 2, pp. 205-214. DOI: 10.1158/1535-7163.MCT-22-0012
        PubMed      DOI
    2.Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer

    Author: Li, Chengxun; Zhang, Jiale; Wu, Qiming; Kumar, Anuj; Pan, Guihong; Kelvin, David J.
    Journal: MOLECULAR CANCER THERAPEUTICS. 2023; Vol. 22, Issue 3, pp. 306-316. DOI: 10.1158/1535-7163.MCT-22-0159
        PubMed      DOI
    3.Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS

    Author: Wang, Xing; Raman, Natasha; Lemtiri-Chlieh, Ghali; Chang, Jinhee; Jagtap, Shreya; Chowdhury, Dipanwita Dutta; Ballew, Matthew; Carrieri, Francesca Anna; Nguyen, Triet; Nugent, Katriana; Peck, Travis; Levine, Michelle S.; Chan, Aaron; Lam, Christine; Malek, Reem; Hoang, Tung; Phillips, Ryan; Cheng, ZhuoAn; Taparra, Kekoa; Connis, Nick; Hann, Christine L.; Holland, Andrew; Tran, Phuoc T.; Lafargue, Audrey; Wang, Hailun
    Journal: MOLECULAR CANCER THERAPEUTICS. 2023; Vol. 22, Issue 4, pp. 519-528. DOI: 10.1158/1535-7163.MCT-22-0191
        PubMed      DOI
    4.Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-KB-Triggered SASP in Cancer-Associated Fibroblasts

    Author: Jin, Ping; Li, Xin; Xia, Yu; Li, Huayi; Li, Xiaoting; Yang, Zong-Yuan; Wang, Zhen; Xu, Cheng; Fang, Tian; Zhou, Dongchen; Xiong, Xiaoming; Wang, Si-Yuan; Xu, Sen; Gao, Qinglei
    Journal: MOLECULAR CANCER THERAPEUTICS. 2023; Vol. 22, Issue 4, pp. 447-458. DOI: 10.1158/1535-7163.MCT-22-0396
        PubMed      DOI
    5.Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer.

    Author: Feng J, Zhang S, Wu K, Wang B, Wong JY, Jiang H, Xu R, Ying L, Huang H, Zheng X, Chen X, Ma S.
    Journal: Mol Cancer Ther. 2016 May;15(5):842-53. doi: 10.1158/1535-7163.MCT-15-0445. Epub 2016 Feb 2.
        PubMed  
    6.Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption.

    Author: Xu L, Luo J, Jin R, Yue Z, Sun P, Yang Z, Yang X, Wan W, Zhang J, Li S, Liu M, Xiao J.
    Journal: Mol Cancer Ther. 2016 May;15(5):854-65. doi: 10.1158/1535-7163.MCT-15-0669. Epub 2016 Feb 9.
        PubMed  
    7.Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.

    Author: Karan G, Wang H, Chakrabarti A, Karan S, Liu Z, Xia Z, Gundluru M, Moreton S, Saunthararajah Y, Jackson MW, Agarwal MK, Wald DN.
    Journal: Mol Cancer Ther. 2016 Apr;15(4):574-82. doi: 10.1158/1535-7163.MCT-15-0467. Epub 2016 Feb 16.
        PubMed  
    8.Long Noncoding RNA PVT1 Promotes Non-Small Cell Lung Cancer Cell Proliferation through Epigenetically Regulating LATS2 Expression.

    Author: Wan L, Sun M, Liu GJ, Wei CC, Zhang EB, Kong R, Xu TP, Huang MD, Wang ZX.
    Journal: Mol Cancer Ther. 2016 May;15(5):1082-94. doi: 10.1158/1535-7163.MCT-15-0707. Epub 2016 Feb 23.
        PubMed  
    9.Chikusetsusaponin IVa Butyl Ester (CS-IVa-Be), a Novel IL6R Antagonist, Inhibits IL6/STAT3 Signaling Pathway and Induces Cancer Cell Apoptosis.

    Author: Yang J, Qian S, Cai X, Lu W, Hu C, Sun X, Yang Y, Yu Q, Gao SP, Cao P.
    Journal: Mol Cancer Ther. 2016 Jun;15(6):1190-200. doi: 10.1158/1535-7163.MCT-15-0551. Epub 2016 Feb 29.
        PubMed  
    10.Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.

    Author: Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, Donahue TR, Hill R.
    Journal: Mol Cancer Ther. 2016 May;15(5):1043-52. doi: 10.1158/1535-7163.MCT-15-0774. Epub 2016 Mar 3.
        PubMed  
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144716.20
    LANCET700115.30
    NEW ENGLAND JOURNAL OF MEDICINE933110.50
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62238.80
    NATURE REVIEWS DRUG DISCOVERY28965.90
    NATURE REVIEWS IMMUNOLOGY35170.80
    Lancet Respiratory Medicine7961.60
    BMJ-British Medical Journal010.20
    BMJ-British Medical Journal010.20
    NATURE MEDICINE49791.90
    同分区等级的其他期刊名称 h-index CiteScore
    JOURNAL OF TRAVEL MEDICINE5115.20
    BEHAVIORAL AND BRAIN SCIENCES1481.50
    Eurosurveillance9022.10
    Emerging Microbes & Infections3119.00
    NUCLEIC ACIDS RESEARCH45228.00
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE714.30
    Annual Review of Nuclear and Particle Science9023.90
    CYTOKINE & GROWTH FACTOR REVIEWS14814.60
    Journal of Extracellular Vesicles027.40
    EMERGING INFECTIOUS DISEASES20213.00


以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

    同领域作者分享投稿经验:共4条 (包含回复)

我来分享

    关闭窗口

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2023 中国: LetPub上海分公司    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960

    增值电信业务经营许可证:沪B2-20211595

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦2103室

    United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451